Close Menu

NEW YORK – Australian genetic testing firm Genetic Technologies said on Wednesday it has entered into definitive agreements with unnamed institutional investors for the purchase of more than 1 million American Depositary Shares at A$1.75 ($1.07) per ADS in a registered direct offering.

Each ADS represents 600 of the firm's ordinary shares, and gross proceeds from the offering, expected to close on or about April 3, is estimated at A$1.8 million ($1.1 million).

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nearly 30,000 COVID-19 tests the UK sent to the US came back as void, according to the Telegraph.

Black principal investigators receive less favorable application scores when seeking US National Institutes of Health grants, the Chronicle of Higher Education reports.

New Scientist reports that both RNA and DNA may have been involved in the emergence of life on Earth.

In Nature this week: new Sperm-seq method enables crossover analysis, tumor-informed detection approach for minimal residual disease, and more.

Jul
15
Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.